Focuses on developing novel immunotherapeutic strategies, such as peptide-antibody conjugates and CD40-agonistic antibodies, to activate tumor-specific T-cells and reduce systemic side effects. Aims to bridge preclinical models to clinical studies in the biotech field.
Investment history, co-investors, and scores — unlock with a subscription.